InvestorsHub Logo
Followers 4
Posts 372
Boards Moderated 0
Alias Born 08/13/2019

Re: Whalatane post# 223953

Saturday, 11/09/2019 6:40:13 PM

Saturday, November 09, 2019 6:40:13 PM

Post# of 425847

Atom ...so we disagree
I expect the FDA to include diabetics with 1 additional risk factor, on statins etc ....to be included on the label BECAUSE they had at least a 12% RRR .

Ezetimibe is to lower LDL cholesterol ..I'm on it ( as well as Vascepa , Repatha etc ) .
I think you might be confused re " dyslipidemia /CVD " .. Everyone in R-IT had some form of dyslipidemia which is what caused their CVD risk factors ...high LDL , high TG/low HDL , High LDL with high TG etc etc

JMO
Kiwi



Dyslipidemia encompasses increased cholesterol (hyperlink). Ezetimibe, as I mentioned in the post you are responding to, is indicated for hypercholesterolemia (i.e. dyslipidemia) (hyperlink). In contrast, Amarin wants to expand their label for dyslipidemia to include REDUCE-IT cardiovascular outcomes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News